Background-Recent studies reported worse outcomes after atrial fibrillation (AF) ablation in patients with metabolic syndrome (MetS 
M
etabolic syndrome is associated with unfavorable hemodynamic, metabolic, and autocrine-paracrine factors that could trigger directly or indirectly atrial cell apoptosis, lymphocyte infiltration, fibroblast proliferation, increased collagen deposition, and myocardial fiber disarray. [1] [2] [3] [4] [5] Renin-angiotensin system and oxidative stress can change the membrane ion channels and modulate the connexin surface expression, leading to slow atrial conduction. [6] [7] [8] [9] [10] [11] [12] This process called electroanatomic remodeling is frequently observed in patients with atrial fibrillation (AF). 13 Increased collagen deposition and matrix volume expansion has been found to correlate with the presence of AF and its persistence. 14, 15 
Clinical Perspective on p 489
Clinical studies demonstrated that obesity, diabetes mellitus, hypertension, and metabolic syndrome (MetS) itself are associated with new-onset AF. [16] [17] [18] [19] [20] Recent trials reported on higher recurrences after radiofrequency catheter ablation (RFCA) of AF in patients with impaired fasting glucose and MetS. [21] [22] [23] [24] [25] Advanced electroanatomic remodeling was proposed as a plausible explanation for these unfavorable outcomes. To date, only few publications reported on the differences in the arrhythmogenic substrate in patients with AF and MetS, so that the missing link between MetS and worse long-term outcomes after RFCA of AF remains unclear. 23, 25 The intuitive concept that electrically silent areas in electroanatomic voltage maps represent areas of left atrial (LA) fibrosis has been recently supported from several MRI studies, demonstrating good correlation between LA hyperenhancement and low voltage areas in electroanatomic maps. 26, 27 In addition, areas of low voltage and fractionated activity are commonly accepted as an electrophysiological representation of delayed conduction velocity in electrically anisotropic tissue. 28 Therefore, LA electroanatomical mapping of lowamplitute and fractionated potentials may have an advantage over the MRI images of LA hyperenhancement, combining both anatomic and electric information.
Objective
We aimed to investigate the peculiarities in LA electroanatomic substrate in patients with MetS and AF and how these differences relate to long-term outcomes between patients with and those without MetS.
Methods

Patient Population and Definition of Metabolic Syndrome
Two hundred thirty-six patients with symptomatic, refractory-tomedical-therapy paroxysmal and persistent AF were prospectively enrolled in the study in the period between June 2010 and June 2011. Previously ablated patients, patients with significant valvular abnormalities, LA diameter in parasternal long axis >60 mm, and intracardiac thrombus were excluded from the study. The study protocol complies with the principles of the Declaration of Helsinki and the local institutional guidelines. All patients provide written informed consent for the procedure and for using and storing of personal data for the purpose of the study.
Paroxysmal AF was defined as self-terminating AF of duration <7 days that requires no electric or pharmacological cardioversion. Persistent AF was defined as a persistent arrhythmia for >7 days or requiring electric or pharmacological cardioversion to terminate or both these conditions. In addition, the duration of AF from the first documented AF episode to ablation was calculated.
MetS was outlined according to the criteria accepted in the National Cholesterol Education Program Adult Treatment Panel III guidelines. MetS was defined as the presence of ≥3 of the following criteria: visceral obesity with waist circumference >88 for women and 102 for men; hypetrigicerydaemia >150 mg/dL; low high-density lipoprotein <40 mg/dL in men and <50 mg/dL in women; hypertension, defined as a continuously elevated blood pressure of >130/85 mm Hg or a history of treated hypertension or both; impaired glucose tolerance >110 mg/dL or a history of diabetes mellitus 2 type or both.
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Blood Sampling
Blood samples were obtained in EDTA test tubes in fasting state. Serum total cholesterol, high-density lipoprotein , and triglycerides were measured directly in serum. Blood samples were analyzed using Dimension RxL Max Integrated Chemistry System; Siemens; Erlangen; Germany.
Catheter Ablation Procedure
Access to the LA was obtained through a single or double transseptal puncture (TSP) using the Brokenbrough needle. The decision for single or double TSP was at the operator's discretion. A steerable introducer (Agilis NxT, St Jude Medical, St. Paul, MN) and in cases of double TSP, a second nonsteerable sheath (Swartz, SL0, St Jude Medical, St. Paul, MN) were introduced in to the LA cavity. Patients without therapeutic anticoagulation at the time of ablation received 5000 UI heparin intravenously before TSP, followed by additional heparin boluses during the procedure to maintain an activated clotting time of 300 to 400 seconds. throughout the ablation. In patients on oral anticoagulation therapy with international normalized ratio 2 to 3, heparin was given first after the TSP.
We used 4-mm irrigated tip ablation catheters (Thermocool, Biosense Webster; Diamond Bar, CA or Cool Flex, St. Jude Medical, St. Paul, MN) with power settings ≤30 W at the posterior wall and ≤45 W elsewhere to perform pulmonary vein isolation. Three dimensinal mapping navigation systems (Carto 3; Biosense Webster, Diamond bar, CA or EnSite Velocity; Endocardial Solutions, St. Paul, MN) were used to facilitate the ablation. A three dimensinal geometry of the LA and the pulmonary veins was obtained and subsequently superimposed on a subtracted three dimensinal computed tomographic image of the LA. PVI was performed by sequential application of radiofrequency energy at the antrum of the pulmonary veins. The end point was isolation of the pulmonary veins with proof of both exit and entrance block. No additional lesions outside the pulmonary veins antral areas were initially performed to avoid inadvertent LA scaring as a consequence of radiofrequency energy application. (Figure 1A and 1B). In cases with AF persistence after the PVI, sinus rhythm was successfully restored using electric cardioversion.
After the isolation of the pulmonary veins, color-coded electoanatomic voltage maps of the LA outside the encircled PV antrum areas in sinus rhythm were created in every patient using ablation catheter as a roving catheter. We examined every beat to exclude mechanically induced premature beats. Potentials with amplitudes >0.5 mV were defined as normal and coded in purple color, and potentials <0.2 mV as low voltage coded in red or gray. 30, 31 In low voltage areas highdensity mapping was performed to delineate them from the high voltage areas. The interpolation was adjusted to 15 in both NavX and Carto cases.
Because a stable catheter-tissue contact is crucial for the accuracy of the voltage maps, we used steerable sheaths to press the mapping catheter more firmly against the LA wall. The consistency of each point was then compared against signal amplitudes of adjacent map points. Last, other characteristics of the signals such as fractionation and signal duration were taken into consideration in addition to the absolute voltage amplitudes. Low voltage and slurred potentials of short duration were discarded. At least 10 points were obtained at each segment.
Additional substrate modification was performed at the operator's discretion. Usually, additional linear lesions were created to eliminate induced LA macro reentry tachycardias or transsecting scar areas. The completeness of the lines was proved using differential pacing to demonstrate the existence of bidirectional block.
( Figure 1C and 1D).
LA atrial low voltage areas were semiquantitatively estimated using a simple low voltage index: low voltage (LoVo) index. The LA surface was divided into 6 segments: roof; posterior wall between left and right pulmonary veins; inferior posterior wall; superior septum above fossa ovalis; inferior septum under fossa ovalis and in front of the right inferior pulmonary vein; lateral wall, corresponding to the ridge between LA appendage velocity and left superior pulmonary vein and mitral isthmus. (Figure 2 ) One point was assigned to each segment with low voltage potentials. Sum of the affected segments has been calculated and presented semiquantitatively as LoVo, ranging between 1 for one affected segment and 6 when all LA segments were affected. Thus, LoVo index can be a simple and quickly obtainable indicator of the amount of LA scarring.
Follow-Up
All patients were seen in the Heart Center Leipzig outpatient clinic at 3, 6, and 12 months. We accepted a 3-month blanking period. Before every scheduled visit, all patients received 7-day Holter ECG recordings to evaluate the recurrence of symptomatic and asymptomatic AF or LA tachycardias. Four patients were lost for follow-up before the sixth month. All other patients (232 patients) completed a 12-month follow-up. Every AF or atrial tachycardia episode lasting >30 minutes detected after the blanking period was defined as recurrence. Patients with recurrences and stable sinus rhythm on antiarrhythmic drugs thereafter were counted as recurrences as well.
Statistical Analysis
Continuous data are presented as mean±SD and categorical data as counts and percents. Student t tests, χ 2 tests, and Fisher exact tests were used to compare groups. Binominal logistic regression was used to calculate the odd ratios and confidence intervals for the presence of low voltage areas and AF recurrence. All covariates were entered into the model on the basis of known or expected clinical relevance and significance in the univariate analysis (2-sided P<0.05). Because nearly all subjects completed 12 months of follow-up, no survival analysis was done. Also, with the focus on 12-month results, no Continuous variables are presented as mean and SD; categorical variable as numbers and percentages-n (%). ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; HDL, high-density lipoprotein; LDL, low-density lipoprotein; and PLAX, parasternal long axis.
repeated measures analysis was done. Tests were run to examine the presence of any significant interactions and to identify possible multicollinearity of the covariates.
Results
Baseline Characteristics
The total studied population included 236 adults with a history of paroxysmal or persistent AF, predominantly men (178 men; 75.4%) with a mean age for the overall cohort: 61.3±9.6 years. MetS was diagnosed in 126 patients (53.4%). In univariate analysis, older age, lower ejection fraction, and larger LA diameter were associated with MetS (Table1).
MetS and LA Low Voltage Areas
Low voltage areas in electroanatomic maps were observed in 58 (46%) patients with MetS, but in only 8 cases (8.2%) without MetS (P<0.0001). The most frequently affected areas in MetS were the posterior wall (35 of 126 patients; 27.8%) and the septum (32 of 126 patients; 25.4%), followed by the LA roof (22 of 126 patients; 17.5%) and rarely the mitral isthmus area (7 of 126 patients; 5.6%; Table 1) In multivariate analysis, after adjustment for age, LA diameter, LA appendage velocity, left ventricular ejection fraction, clinical presentation of AF (paroxysmal or persistent), treatment with angiotensin-converting enzyme inhibitor/angiotensin receptor blockers, and statins, MetS was the strongest independent predictor of low voltage areas in LA: odds ratio (OR) 11.64; 95% confidence interval (CI, 4.381-30.903); P<0.0001. Age and persistent AF were also independent predictors of the presence of LA substrate (Table 2) .
When analyzed separately, among the components of the MetS, only the arterial hypertension and diabetes mellitus were independently associated with the presence of LA low voltage areas with OR, 6.973; 95% CI, 1.556 to 31.25; P=0.011 for arterial hypertension and OR, 2.68; 95% CI, 1.061 to 6.773; P=0.037 for diabetes mellitus (Table 3) . However, the MetS has higher predictive value than the combined arterial hypertension and diabetes mellitus values: OR, 11.64; 95% CI, 4.381-30.903; P<0.0001.
MetS and LA Low Voltage Areas in Relation to Long-Term Outcomes After AF Ablation
Four patients were lost for follow-up and the analysis for AF recurrence was performed for the rest 232 patients. AF recurrence free from antiarrhythmic drugs at 6-and 12-month follow-up was observed in 78 patients (33.6%) and 92 patients (39.7%), respectively.
At 6-month follow-up, 46 patients (37.1%) with MetS and 32 patients (29.6%) without MetS (P=0.230) had experienced AF recurrence. At 12-month follow-up, the AF recurrence was 42.7% (53 patients) in MetS versus 36.1% (39 patients) in the non-MetS group (P=0.303). However, the AF recurrence at 6 months was significantly higher in patients with LA low voltage areas: 49.2% (32 patients) in the LA low voltage group versus 27.5% (46 patients) in the group without LA low voltage areas (P=0.002); the 12-month AF recurrence free from antiarrhythmic drug use was 52.3% (34 patients) in the LA low voltage group versus 34.7% (58 patients) in the group without LA low voltage areas (P=0.014; Figure 3) .
In univariate analysis, the probability of AF recurrence at 12-month follow-up was twice as high as in the presence of LA low voltage areas: OR, 2.06; 95% CI, 1.15-3.68; P=0.015. In multivariate analysis after adjustment for relevant clinical confounders (age, sex, AF duration, persistence of AF, LA dimension, LA appendage velocity, antiarrhythmic drugs after discharge, MetS), presence of LA low voltage areas was the strongest independent predictor of AF recurrence at 12 months: OR, 2.99; 95% CI, 1.36-6.56; P=0.006. In addition, female sex and duration of AF were independent predictors of combined AF/LA macro reentry tachycardias recurrence at 12 months. MetS itself was not associated with AF recurrence (Table 4) .
Analysis of the patients with LA electroanatomic substrate (LoVo >0) identified that LoVo Index, AF duration, and female sex are independent predictors of AF recurrence at 12 months. For every unit of LoVo index, the probability of AF recurrence at 12 months increases with 84% (Table 5) .
Discussion
MetS is a common clinical condition in patients referred for AF ablation. Previous studies proved that MetS is an independent predictor of AF recurrence after PVI. [21] [22] [23] [24] However, little is known about the electrophysiological substrate in patients with MetS, also the possible reasons for this unfavorable relation remain unclear. Previously, Chang et al 23 reported on higher AF recurrence rates after RFCA in MetS. They have demonstrated differences in the characteristics and distribution of the complex fractionated atrial electrograms in patients with and those without MetS. 23 However, the presence and localization of complex fractionated atrial electrograms during AF usually do not coincide with the low voltage areas in sinus rhythm. Although many theories tried to explain their nature, it seems that complex fractionated atrial electrograms are more presentation of electric than anatomic inhomogeneity in LA.
To the best of our knowledge, the impact of MetS on LA low voltage areas has not been previously studied. Because recent publications demonstrated good correlation between MRI-detected areas of atrial fibrosis and LA low voltage areas, we used color-coded voltage mapping in sinus rhythm to delineate LA areas with low voltage and fractionated potentials. 26, 27 The presence of low voltage areas in patients with MetS was observed in 46%, compared with only 8.2% in non-MetS, which supports the hypothesis that MetS alters the electrophysiological substrate for AF in affected individuals. Furthermore, the probability of LA low voltage areas was ≈12× higher in the presence of MetS. Interestingly, the spatial distribution of low voltage areas in MetS showed predilection on posterior and septal walls, which coincides with the observed LA scar distribution in necropsy specimens of LA in patients with AF. 15 In addition to MetS, other factors (eg, aging process, AF persistence, and sex differences) can contribute to the LA remodeling process.
In a recently published trial by Mohanty et al 21 in ≈1500 patients after RFCA of AF, MetS was associated with unfavorable long-term outcomes, but the impact of electroanatomic substrate on the AF recurrences was not analyzed. In contrast, we demonstrated that MetS did not influence AF recurrence directly; however, it was strongly associated with the extent of electroanatomic remodeling process. We observed that for every additionally affected LA segment, the probability of AF recurrence at 12 months increased with 84%. Importantly, in the study by Mohanty et al. 21 MetS was associated with worse outcomes after RFCA only in persistent AF, suggesting more advanced disease in this subgroup. This is in concordance with our findings that persistent AF, in addition to MetS, was associated with the presence of low voltage areas and that the duration of AF was a predictor of AF recurrence as well. We suggest that observed from Mohanty et al, 21 higher AF recurrence rate in the subgroup with MetS and persistent AF may be attributed more to the presence of vast LA low voltage areas than to the MetS itself. Differences in MetS definition, follow-up period, and ablation approach can also explain the observed outcome difference.
Although our study did not prove a direct association between MetS and AF recurrence after RFCA, it suggested that LA low voltage areas may be the missing link between the 2. Through associated oxidative stress and unfavorable hemodynamic, metabolic, and cytokine influences, MetS leads to development of atrial fibrosis and slow conduction that can be visualized in LA voltage maps as areas of fractionated and low voltage potentials. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Our study demonstrated that advanced electric remodeling and the presence of nonpulmonary vein substrate for AF must be expected in MetS and that the presence and extent of LA low voltage areas were associated with more AF recurrences, a finding supported by a previous study. 32 We suggest that in addition to PVI, extensive ablation to modify these low voltage areas may be necessary to achieve better long-term outcomes in patients with MetS.
Limitations
It is a single-center study and ablation approach adopted in our center may influence the recurrence rates. Although voltage maps were obtained after circumferential pulmonary vein isolation, but before substrate modification in LA outside pulmonary vein regions, limited low voltage areas could be seen in proximity to the circumferential lines; however, these were excluded by calculating LoVo score. Although there was no difference in AF recurrence between patients with and those without MetS at 1 year, probably such difference could be observed at a longer follow-up period; however, the impact of LA low voltage on AF recurrence was evident even after a 1-year follow-up. We preferred to use odd ratios instead of hazard ratios, because the high incidence of asymptomatic AF episodes after RFCA precludes the accurate definition of the time to first recurrence without using continuous rhythm monitoring.
Conclusions
MetS was not associated with worse outcomes after RFCA of AF, but LA low voltage areas were more frequently observed in patients with MetS. The presence and extent of LA low voltage areas may influence the long-term outcomes after catheter ablation.
